Search Results

There are 64784 results for: content related to: A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C

  1. You have free access to this content
    Immunotherapy for renal carcinoma: theoretical basis and current standard of care

    British Journal of Clinical Pharmacology

    Volume 50, Issue 6, December 2000, Pages: 521–529, Paul A. Vasey

    Article first published online : 9 OCT 2008, DOI: 10.1046/j.1365-2125.2000.00300.x

  2. You have free access to this content
    Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count≥300 cells/μL who were assigned to 7.5 MIU interleukin-2

    HIV Medicine

    Volume 8, Issue 2, March 2007, Pages: 112–123, The ESPRIT Research Group

    Article first published online : 7 MAR 2007, DOI: 10.1111/j.1468-1293.2007.00440.x

  3. You have free access to this content
    Natural history and therapy of metastatic renal cell carcinoma


    Volume 80, Issue 7, 1 October 1997, Pages: 1198–1220, Ronald M. Bukowski

    Article first published online : 20 NOV 2000, DOI: 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H

  4. Interaction of recombinant interleukin-2 with liposomal bilayers

    Journal of Pharmaceutical Sciences

    Volume 87, Issue 6, June 1998, Pages: 707–714, Frank J. Koppenhagen, Antonie J. W. G. Visser, James N. Herron, Gert Storm and Daan J. A. Crommelin

    Article first published online : 12 JUN 2000, DOI: 10.1021/js9704386

  5. Controlled release of interleukin-2 from chitosan microspheres

    Journal of Pharmaceutical Sciences

    Volume 91, Issue 5, May 2002, Pages: 1245–1251, Suna Özbaş-Turan, Julide Akbuǧa and Cenk Aral

    Article first published online : 20 MAR 2002, DOI: 10.1002/jps.10122

  6. Interleukin-2: Use in solid tumors


    Volume 11, Issue 1, 1993, Pages: 26–32, R. M. Bukowski, D. Mclain, T. Olencki, G. T. Budd and S. A. Murthy

    Article first published online : 23 DEC 2008, DOI: 10.1002/stem.5530110106

  7. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy

    Intervention Review

    The Cochrane Library

    Kelvin KW Chan, Anne-Marie Glenny, Jo C Weldon, Susan Furness, Helen V Worthington and Helen Wakeford

    Published Online : 1 DEC 2015, DOI: 10.1002/14651858.CD010341.pub2

  8. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters

    Journal of Experimental Therapeutics and Oncology

    Volume 3, Issue 4, July 2003, Pages: 205–219, Giovanni Mantovani, Clelia Madeddu, Giulia Gramignano, Maria Rita Lusso, Miria Mocci, Elena Massa, Luca Ferreli, Giorgio Astara, Antonio Macciò and Roberto Serpe

    Article first published online : 19 SEP 2003, DOI: 10.1046/j.1359-4117.2003.01096.x

  9. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2)

    Radiation Oncology Investigations

    Volume 5, Issue 2, 1997, Pages: 54–61, I.-M. Jürgenliemk-Schulz, I.B. Renes, D.H. Rutgers, L.A. Everse, M.R. Bernsen, W. Den Otter and J.J. Battermann

    Article first published online : 7 DEC 1998, DOI: 10.1002/(SICI)1520-6823(1997)5:2<54::AID-ROI3>3.0.CO;2-I

  10. You have free access to this content
    Protective Effect of Recombinant Human Interleukin-2 against Lethal Infection Caused by Klebsiella pneumoniae

    Microbiology and Immunology

    Volume 34, Issue 2, February 1990, Pages: 185–195, Yuji Iizawa, Masafumi Nakao, Masahiro Kondo and Toshiyuki Yamazaki

    Article first published online : 14 NOV 2013, DOI: 10.1111/j.1348-0421.1990.tb01003.x

  11. Recombinant Interleukin-2

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 14, Issue 6, November-December 1994, Pages: 635–656, Dr. Jill K. Bruton and Jim M. Koeller

    Article first published online : 18 JAN 2012, DOI: 10.1002/j.1875-9114.1994.tb04156.x

  12. You have free access to this content
    Impact of product-related factors on immunogenicity of biotherapeutics

    Journal of Pharmaceutical Sciences

    Volume 100, Issue 2, February 2011, Pages: 354–387, Satish Kumar Singh

    Article first published online : 25 AUG 2010, DOI: 10.1002/jps.22276

  13. Recombinant interleukin 2-activated natural killer cells regulate IgG2a production

    European Journal of Immunology

    Volume 20, Issue 8, August 1990, Pages: 1781–1787, Sebastián Amigorena, Christian Bonnerot, Wolf Herman Fridman and Jean-Luc Teillaud

    Article first published online : 17 NOV 2005, DOI: 10.1002/eji.1830200824

  14. Adhesion molecule expression and leucocyte trafficking following immunotherapy with recombinant interleukin-2


    Volume 28, Issue 4, April 1996, Pages: 301–308, D.W. MILES, L.C. HAPPERFIELD, L.G. BOBROW and R.D. RUBENS

    Article first published online : 27 NOV 2003, DOI: 10.1046/j.1365-2559.1996.d01-430.x

  15. The roles of interleukin 2 and interferon-γ in human B cell activation, growth and differentiation

    European Journal of Immunology

    Volume 16, Issue 8, 1986, Pages: 925–932, Diane F. Jelinek, Judy B. Splawski and Peter E. Lipsky

    Article first published online : 9 DEC 2005, DOI: 10.1002/eji.1830160809

  16. Interaction of recombinant interferons with recombinant interleukin-2: Differential effects on natural killer cell activity and interleukin-2-activated killer cells

    International Journal of Cancer

    Volume 37, Issue 5, 15 May 1986, Pages: 787–793, Michael J. Brunda, Deborah Tarnowski and Viveca Davatelis

    Article first published online : 17 JUL 2006, DOI: 10.1002/ijc.2910370522

  17. Recombinant interleukin-2 (rIL-2) in acquired immune deficiency syndrome (AIDS): Preliminary report in patients with lymphoma associated with HIV infection

    European Journal of Haematology

    Volume 49, Issue 1, July 1992, Pages: 1–6, Dr. P. Mazza, M. Bocchia, F. Tumietto, P. Costigliola, O. Coronado, G. Bandini, R. Conte, E. Ricchi, N. Vianelli, E. Raise, A. Fondacaro, M. C. Re, N. Vignoli, F. Chiodo and S. Tura

    Article first published online : 24 APR 2009, DOI: 10.1111/j.1600-0609.1992.tb00905.x

  18. You have free access to this content
    Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2

    Clinical & Experimental Immunology

    Volume 92, Issue 2, May 1993, Pages: 185–193, J. W. GRATAMA, R. J. BRUIN, C. H. J. LAMERS, R. OOSTEROM, E. BRAAKMAN, G. STOTER and R. L. H. BOLHUIS

    Article first published online : 28 JUN 2008, DOI: 10.1111/j.1365-2249.1993.tb03378.x

  19. You have free access to this content
    The Interaction of Recombinant IL-2 with Human Resting Lymphocytes

    Microbiology and Immunology

    Volume 31, Issue 1, January 1987, Pages: 59–74, Rieko Iseki, Yukio Koide, Ryuzo Ueda, Nobuo Kondo, Junji Hamuro and Takato O. Yoshida

    Article first published online : 14 NOV 2013, DOI: 10.1111/j.1348-0421.1987.tb03068.x

  20. Electroblotting proteolytic products from native gel for direct N-terminal sequence analysis: An approach for studying protein-protein interaction


    Volume 14, Issue 1, 1993, Pages: 847–851, Feng Wang, Chang Su, Kurt Hollfelder, Doreen Waddington and Dr. Yu-Ching E. Pan

    Article first published online : 13 APR 2005, DOI: 10.1002/elps.11501401135